GALT — Galectin Therapeutics Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

Trend Edge Setup Score

Trend Edge rates GALT Bullish with a Setup Score of 28, net conviction 33, actionability 24. How the Setup Score works →

Total Setup Score28
Directional BiasBullish
Net Conviction33
Actionability24 (in range)

Key signals behind this score

About Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$3.99
Market Cap$360M
Float47.8M
Shares Outstanding100.8M
P/E (Forward)4.54
vs. Analyst Target+175.7% to analyst PT
Dividend RateNone
Analyst Target Price$11.00 (1 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$23.5M -$36,000 -$23.3M
2021 N/A -$30.5M -$41,000 -$30.0M
2022 N/A -$38.8M -$32,000 -$37.7M
2023 N/A -$41.1M -$33,000 -$38.2M
2024 N/A -$47.0M -$37,000 -$41.5M
2025 N/A -$30.8M N/A -$23.5M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Sep 2025 N/A -$8.2M
Dec 2025 N/A -$5.5M
Mar 2026 N/A -$5.0M
Jun 2026 N/A -$9.1M

Ownership & Float

Insider Ownership53.1%
Institutional Ownership15.6%
Short Float18.2%
% of All Funds Holding1.13%
Number of Funds Holding99

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$3.87Near-term / short-term trend
Weekly40-Week SMA$3.34Medium-term trend
Weekly80-Week SMA$3.16Cyclical trend (business cycle)
Weekly200-Week SMA$2.45Secular trend (multi-year)
Monthly10-Month SMA$3.49Near-term monthly trend
Monthly20-Month SMA$3.08Medium-term monthly trend
Monthly40-Month SMA$2.62Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$4.50 resistance 1.22x 0 months ago
$2.60 support 2.25x 1 months ago
$5.70 resistance 1.81x 7 months ago
$1.30 support 2.91x 13 months ago

Historical Earnings Reactions (93 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.34% 0.00% 33.33% 10.32% -8.70%
1 Day -1.35% -1.41% 36.56% 19.05% -16.67%
1 Week -0.38% -1.30% 40.86% 56.49% -57.14%
2 Weeks -0.72% -1.58% 39.13% 63.60% -57.14%
1 Month 1.94% -5.81% 38.04% 149.24% -59.03%

Next earnings: November 2, 2026 (67 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan4.6%45.8%24
Feb27.9%70.8%24
Mar-0.9%45.8%24
Apr12.2%45.8%24
May-2.8%29.2%24
Jun5.1%50.0%24
Jul2.8%50.0%24
Aug-3.1%39.1%23
Sep3.9%52.2%23
Oct-5.1%45.8%24
Nov-6.5%33.3%24
Dec-3.5%37.5%24

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.09% 40.5% 1132
Tuesday 0.41% 43.3% 1239
Wednesday 0.42% 41.6% 1237
Thursday 0.09% 42.6% 1214
Friday 0.06% 43.4% 1208

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 15.6%

Insider Transactions — Smart Summary

Total insider ownership: 53.1%

12-Month Insider Activity Summary

Total Filings33
Net Value-$2.4M
Net Shares Change-353,895
% of Float-0.7%
C-Suite Filings21
Clusters Detected3

Key Insiders

NameTitleNet ValueFilingsActivity
10X Fund, L.P. -$1.7M 5 5 sell
Jamil Khurram Chief Medical Officer -$447,474.94 1 N/A
Shlevin Harold H. -$132,823.962 1 N/A
FREEMAN KEVIN D +$39,028 1 1 buy
ELDRED KARY +$6,032 2 2 buy

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-11-05 – 2025-11-19 10 4 -$1.3M 9 C-suite
2025-12-08 – 2025-12-19 7 4 -$2.1M 2 C-suite
2025-12-23 – 2026-01-06 6 5 -$765,769.313 4 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2025-12-23 FREEMAN KEVIN D +$39,028 Transaction at $3.55, now +12.5%
2025-12-23 ELDRED KARY +$5,222 Transaction at $3.73, now +7.0%
2026-02-09 ELDRED KARY +$810 Transaction at $2.70, now +47.8%
2025-12-08 10X Fund, L.P. -$920,859.851 Transaction at $5.68, now -29.8%
2025-12-18 10X Fund, L.P. -$204,335.46 Transaction at $6.66, now -40.1%
2025-11-12 10X Fund, L.P. -$210,000 Transaction at $5.25, now -24.0%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Galectin Therapeutics Inc (GALT) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for GALT on Trend Edge →